glp 1 sales GLP-1 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 Exploring the Growth of GLP-1
Description
Both medications are taken as once-weekly subcutaneous injections and work best alongside a reduced-calorie diet and regular physical activity
That distinction applies to both drugs
The FDA has warned patients to be cautious with unapproved GLP-1 products and notes that compounded drugs are not reviewed by the agency for safety, effectiveness, or quality before marketing
However, many insurance companies do not cover weight loss medications such as Wegovy and Zepbound when used solely for weight reduction
